Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

ConferencePADCEVVYLOYpembrolizumabPositive

AI Analysis

Summary

Astellas Pharma presented data at ESMO 2026 demonstrating durable survival benefits for PADCEV (enfortumab vedotin) combined with pembrolizumab in advanced bladder cancer, and highlighted VYLOY (zolbetuximab) research in gastric cancer treatment.

Outcome Details

Data presented at ESMO 2026 highlighting durable survival benefit for PADCEV plus pembrolizumab in advanced bladder cancer and VYLOY research in gastric cancer

Importance:5/10

Sentiment:

0.60

oncologybladder cancergastric cancerESMO 2026clinical datacombination therapy

Related Companies

$ALPMY

Read the original article

Published by PR Newswire Pharma on October 6, 2026 11:30 PM

Read Original